修订版MALT-IPI:一种识别结外边缘区淋巴瘤高危患者的新预测模型
研究基于397例结外边缘区淋巴瘤(EMZL)患者数据构建修订版MALT-IPI,并在两个独立队列(爱荷华大学/梅奥诊所n=297、IELSG-19研究n=400)中验证。该指数以年龄>60岁、LDH升高、III-IV期各1分及多黏膜部位(MMS)2分计分(0-5分),将患者分为四组,高危组(≥3分)无进展生存风险比为8.48。
要点
- 修订版MALT-IPI包含年龄>60岁、LDH升高、III-IV期(各1分)及多黏膜部位(2分)。
- 训练队列中高危组(≥3分)相比低危组(0分)的PFS风险比为8.48。
- 外部验证队列中该指数表现与训练队列相似。
核心结论
- 修订版MALT-IPI是一种以疾病特征为核心的新指数,能稳健地进行风险分层,识别出疾病进展较早的患者组。
研究设计与样本
- 研究在大型数据集(n=397)中推导修订版MALT-IPI,并在两个独立队列(爱荷华大学/梅奥诊所n=297和IELSG-19研究n=400)中进行验证。
主要发现
- 训练队列中,修订版MALT-IPI定义四个风险组:低危(0分,参照组)、低中危(1分,HR=1.85,p=.008)、中高危(2分,HR=3.84,p<.0001)和高危(≥3分,HR=8.48,p<.0001)。
- 修订版MALT-IPI在外部验证队列中的表现与训练队列相似。
关键数值与推荐
- 修订版MALT-IPI评分范围为0-5分,年龄>60岁、LDH升高、III-IV期各计1分,多黏膜部位(MMS)计2分。
临床怎么用
- 修订版MALT-IPI可使临床试验和实践中对EMZL患者的管理更加按疾病调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Extranodal marginal zone lymphoma (EMZL) is a heterogeneous disease with a subset of patients exhibiting a more aggressive course. We previously reported that EMZL with multiple mucosal sites (MMS) at diagnosis is characterized by shorter survival. To better recognize patients with different patterns of progression-free survival (PFS) we developed and validated a new prognostic index primarily based on patient's disease characteristics. We derived the "Revised mucosa-associated lymphoid tissue International Prognostic Index" (Revised MALT-IPI) in a large data set (n = 397) by identifying candidate variables that showed highest prognostic association with PFS. The revised MALT-IPI was validated in two independent cohorts, from the University of Iowa/Mayo Clinic (n = 297) and from IELSG-19 study (n = 400). A stepwise Cox regression analysis yielded a model including four independent predictors of shorter PFS. Revised MALT-IPI has scores ranging from 0 to 5, calculated as a sum of one point for each of the following- age >60 years, elevated LDH, and stage III-IV; and two points for MMS. In the training cohort, the Revised MALT-IPI defined four risk groups: low risk (score 0, reference group), low-medium risk (score 1, HR = 1.85, p = .008), medium-high risk (score 2, HR = 3.84, p < .0001), and high risk (score 3+, HR = 8.48, p < .0001). Performance of the Revised MALT-IPI was similar in external validation cohorts. Revised MALT-IPI is a new index centered on disease characteristics that provides robust risk-stratification identifying a group of patients characterized by earlier progression of disease. Revised MALT-IPI can allow a more disease-adjusted management of patients with EMZL in clinical trials and practice.
引用
- Alderuccio JP, Reis IM, Habermann TM, et al. Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma. Am J Hematol. 2022. PMID: 36057138. doi:10.1002/ajh.26715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。